IL134592A0 - Compositions comprising camptothecin compounds for the treatment of cancer with reduced side effects - Google Patents

Compositions comprising camptothecin compounds for the treatment of cancer with reduced side effects

Info

Publication number
IL134592A0
IL134592A0 IL13459299A IL13459299A IL134592A0 IL 134592 A0 IL134592 A0 IL 134592A0 IL 13459299 A IL13459299 A IL 13459299A IL 13459299 A IL13459299 A IL 13459299A IL 134592 A0 IL134592 A0 IL 134592A0
Authority
IL
Israel
Prior art keywords
cancer
compositions
treatment
side effects
reduced side
Prior art date
Application number
IL13459299A
Other languages
English (en)
Original Assignee
Univ George Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ George Washington filed Critical Univ George Washington
Publication of IL134592A0 publication Critical patent/IL134592A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL13459299A 1998-06-18 1999-06-18 Compositions comprising camptothecin compounds for the treatment of cancer with reduced side effects IL134592A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8978198P 1998-06-18 1998-06-18
PCT/US1999/013906 WO1999065493A1 (en) 1998-06-18 1999-06-18 Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects

Publications (1)

Publication Number Publication Date
IL134592A0 true IL134592A0 (en) 2001-04-30

Family

ID=22219554

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13459299A IL134592A0 (en) 1998-06-18 1999-06-18 Compositions comprising camptothecin compounds for the treatment of cancer with reduced side effects

Country Status (7)

Country Link
EP (1) EP1003516A4 (de)
JP (1) JP2002518332A (de)
CN (1) CN1325305A (de)
AU (1) AU764370B2 (de)
CA (1) CA2300892A1 (de)
IL (1) IL134592A0 (de)
WO (1) WO1999065493A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2300892A1 (en) * 1998-06-18 1999-12-23 The George Washington University Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
DE60030283T2 (de) 1999-05-17 2007-09-20 Cancer Research Ventures Ltd. Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
CA2295429A1 (en) * 2000-01-06 2001-07-06 Michael Michael Treatment or prevention of diarrhea
US7691872B2 (en) * 2001-03-20 2010-04-06 University Of Kentucky Research Foundation Methods and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds
AU2007232206B2 (en) 2006-03-30 2013-04-04 Drais Pharmaceuticals, Inc. Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
JP5919593B2 (ja) * 2006-10-11 2016-05-18 フージョン アンティボディーズ リミテッド 併用療法
CN106999468B (zh) * 2014-10-21 2019-10-25 强普生技股份有限公司 熊脱氧胆酸和水飞蓟素改进cpt-11疗效和毒性的制药用途
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
CN107281462A (zh) * 2017-08-21 2017-10-24 滨州医学院 沙奎拉韦减轻伊立替康毒性的医药新用途
US11000540B1 (en) * 2019-11-22 2021-05-11 Al Siamon Treatment for reducing adverse events including chemotherapy discomfort and other conditions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894029A (en) * 1971-08-26 1975-07-08 Basf Ag Production of camptothecin and camptothecin-like compounds
US4294819A (en) * 1980-08-18 1981-10-13 Bristol-Myers Company Alkaline analgesic capsule
NZ232346A (en) * 1989-02-07 1992-03-26 Duphar Int Res Effervescent oral rehydration solution comprising saccharides, amino acids and bicarbonate salts
HU9202318D0 (en) * 1991-07-22 1992-10-28 Bristol Myers Squibb Co Method for preparing medical preparatives containing didesoxi-purine nucleoside
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
DK66493D0 (da) * 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
GB9417524D0 (en) * 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
AU3684395A (en) * 1994-10-06 1996-05-02 Leon T. Atlas Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
JPH10201821A (ja) * 1997-01-23 1998-08-04 Material Eng Tech Lab Inc 医療用容器
CA2300892A1 (en) * 1998-06-18 1999-12-23 The George Washington University Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects

Also Published As

Publication number Publication date
EP1003516A1 (de) 2000-05-31
EP1003516A4 (de) 2006-07-12
CA2300892A1 (en) 1999-12-23
CN1325305A (zh) 2001-12-05
WO1999065493A1 (en) 1999-12-23
AU764370B2 (en) 2003-08-14
JP2002518332A (ja) 2002-06-25
WO1999065493A9 (en) 2000-03-23
AU5083399A (en) 2000-01-05

Similar Documents

Publication Publication Date Title
HUP0201436A3 (en) Methods and compositions for treating solid tumors
AU6147401A (en) Compositions and methods for the treatment of cancer
AU2212299A (en) Compositions and methods for the treatment of tumor
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
SI1176964T1 (sl) Uporaba et743 za zdravljenje raka
IL148579A0 (en) Oncolytic combinations for the treatment of cancer
NZ512210A (en) Camptothecin analogs useful for treating cancer and leukemia
IL134592A0 (en) Compositions comprising camptothecin compounds for the treatment of cancer with reduced side effects
IL124650A0 (en) Methods and therapeutic compositions for treating cancer
GB9816234D0 (en) Compounds for use in the treatment of inflammation
IL143212A0 (en) Compositions and methods for the treatment of tumor
IL141426A0 (en) Compositions and methods for the treatment of tumor
HUP0402341A3 (en) Compositions containing thiazol-2-ylamines for the treatment of cancer
HUP0101947A3 (en) Combination for the treatment of tumors
IL133760A0 (en) Composition for the treatment of dandruff
GB9800640D0 (en) Compositions for the reduction of scarring
AU5706500A (en) Medicinal compositions for treating colorectal cancer
IL148815A0 (en) Substituted pyrroles as antiproliferative agents for the treatment of cancer
GB9819999D0 (en) Treatment of cancer
AU3412600A (en) Peroxovanadium compounds as antineoplastic agents for the treatment of cancer
GB9904252D0 (en) Composition for the treatment of pain

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees